To identify HCC earlier in those both on—and off—antiviral therapy, it is recommended that all Indigenous Australians ≥50 years of age receive 6-monthly ultrasound surveillance for HCC, with or without alpha-fetoprotein (AFP) [6, 7]. The gene discussed is AFP; the disease is hepatocellular carcinoma.